Aberdeen Group’s Nektar Therapeutics NKTR Stock Holding History

Aberdeen Group’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-750	Closed	-$36K	–	921
2022 Q3	$36K	Hold	750	–	–	﹤0.01%	925
2022 Q2	$43K	Hold	750	–	–	﹤0.01%	948
2022 Q1	$61K	Hold	750	–	–	﹤0.01%	975
2021 Q4	$152K	Hold	750	–	–	﹤0.01%	1041
2021 Q3	$202K	Hold	750	–	–	﹤0.01%	1035
2021 Q2	$193K	Hold	750	–	–	﹤0.01%	1003
2021 Q1	$225K	Hold	750	–	–	﹤0.01%	974
2020 Q4	$191K	Hold	750	–	–	﹤0.01%	945
2020 Q3	$186K	Hold	750	–	–	﹤0.01%	925
2020 Q2	$261K	Hold	750	–	–	﹤0.01%	906
2020 Q1	$201K	Hold	750	–	–	﹤0.01%	895
2019 Q4	$243K	Sell	750 -3,679	-83%	-$1.07M	﹤0.01%	920
2019 Q3	$1.21M	Sell	4,429 -5,596	-56%	-$2.05M	﹤0.01%	776
2019 Q2	$5.35M	Sell	10,025 -4,250	-30%	-$2.13M	0.01%	626
2019 Q1	$7.2M	Sell	14,275 -686	-5%	-$407K	0.02%	561
2018 Q4	$7.44M	Buy	14,961 +4,160	+39%	+$2.51M	0.02%	500
2018 Q3	$9.88M	Buy	10,801 +7,536	+231%	+$6.43M	0.02%	487
2018 Q2	$2.39M	Buy	3,265 +611	+23%	+$705K	﹤0.01%	706
2018 Q1	$4.23M	Buy	2,654 +1,704	+179%	+$2.2M	0.01%	577
2017 Q4	$851K	Sell	950 -466	-33%	-$276K	﹤0.01%	743
2017 Q3	$510K	Buy	+1,416	New	+$443K	﹤0.01%	754

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Aberdeen Group's NKTR Position: Q4 2022 in Review

Aberdeen Group sold out of Nektar Therapeutics (NKTR) in Q4 2022, closing a stake of 750 shares — an estimated $36K sold.

Aberdeen Group first reported a position in NKTR in Q3 2017 and held it in 21 quarters. The position peaked at $9.88M in Q3 2018. 214 funds tracked by Wall St. Rank hold NKTR as of Q4 2022.

Aberdeen Group reported no remaining Nektar Therapeutics position as of Q4 2022 after selling out during the quarter.
Aberdeen Group sold 750 Nektar Therapeutics shares in Q4 2022, an estimated $36K.
Aberdeen Group first reported a position in Nektar Therapeutics in Q3 2017 and held it in 21 quarters.
Aberdeen Group's Nektar Therapeutics position peaked at $9.88M in Q3 2018.
214 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2022.

Based on Aberdeen Group's 13F filing for Q4 2022, filed 10 Feb 2023.